Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis - Wikidata - wikimedia - TriplyDB

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

http://www.wikidata.org/entity/Q33421419

about

Mitochondrial determinants of cancer health disparities.

P2860

Q39294200-A98549F5-DF2A-4A22-BC83-C8FF8EBDF934

P2860

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

http://www.wikidata.org/entity/Q33421419

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

@ast

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

@en

type

label

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

@ast

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

@en

prefLabel

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

@ast

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

@en

P1433

Q33421419-4423B227-497E-489E-91F9-22C0FB7BF2F0

P1476

Q33421419-EB2C37CC-B07B-411C-83C6-DF0127F36118

P2093

Q33421419-09026B3A-1D04-49CF-B60E-4F54D81E6211

Q33421419-0DF4DA87-6CEE-40B4-B21B-F44774620C5F

Q33421419-38B115F0-3E77-4183-9ACE-50567C2235B3

Q33421419-50F9F0C4-C494-41E7-B668-A40A8D972A35

Q33421419-68D55BD8-C6A5-4054-AAA5-3BDC0C2D2461

Q33421419-A2CEAA21-F100-4E0C-B588-F577B109F3A1

Q33421419-A494C8DC-2723-4E3E-B5EC-ABD31212D3EA

Q33421419-B9794F87-E770-4254-962C-437E2D4AEFE1

Q33421419-F241A217-5CE1-4668-BC27-683DC9762AA6

P2860

Q33421419-0273D6B9-B209-45D5-98C4-63AF941FEBD7

Q33421419-0B11DB3E-C130-4E75-9384-CFA0A44545F7

Q33421419-12738C61-7FC3-4E95-9A96-4112312D1F5A

Q33421419-2594FDBC-3D02-4262-B468-B1646EBF8F53

Q33421419-268EF65C-2133-439A-A2E7-99AD1C4794C2

Q33421419-28DEE93C-9B9C-4DED-B5B4-1360F3635DC3

Q33421419-3E9943F4-0DC6-4439-8614-E01E62AA0CC3

Q33421419-406BB0DF-2E07-404D-A8A9-BE0E743C34B9

Q33421419-4719BBED-D4D1-4941-8265-26B66E4B96B9

Q33421419-4AE109E4-B5F5-44D4-A380-E413CBDDDF16

P304

Q33421419-A8F3B81D-5660-40F7-843C-CBCFD4E6C83D

P31

Q33421419-59136B3F-F3B8-42D4-8FE5-83EDCF392151

P356

Q33421419-EDC87772-938E-4D75-BDE6-5CBD326B8978

P433

Q33421419-796AFCF9-C5BC-403F-B59F-DF555DBEE984

P478

Q33421419-33C11E1C-537B-4F50-8052-A696BF65690B

P577

Q33421419-FA0E819A-E875-42E1-B19F-6344B216E813

P698

Q33421419-F0016C81-0297-40AC-AEAE-B096B190884A

P932

Q33421419-BCD329BC-E139-4C04-B85B-6898AD3889A4

P356

J.ISSN.2218-6751.2012.06.01

P1433

Translational lung cancer research

P1476

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

@en

P2093

Daoyuan Wang

http://www.w3.org/2001/XMLSchema#string

Dong Wei

http://www.w3.org/2001/XMLSchema#string

Fahad Aziz

http://www.w3.org/2001/XMLSchema#string

Huanyi Liu

http://www.w3.org/2001/XMLSchema#string

Hui Gao

http://www.w3.org/2001/XMLSchema#string

Peng Cheng

http://www.w3.org/2001/XMLSchema#string

Tao Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaomei Su

http://www.w3.org/2001/XMLSchema#string

Xin Ding

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Cancer statistics, 2008

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Operating characteristics of a rank correlation test for publication bias

Quantifying heterogeneity in a meta-analysis

Meta-analysis in clinical trials

Erlotinib in previously treated non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

129-144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2218-6751.2012.06.01

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25806169

http://www.w3.org/2001/XMLSchema#string

P932

4367576

http://www.w3.org/2001/XMLSchema#string